This second part of a 3-part supplement series to The American Journal of Managed Care addresses various clinical and economic aspects of statin therapy in treating dyslipidemia.
Lori Funk, PharmD
Cape Fear Valley Health System
Highsmith-Rainey Memorial Hospital
Fayetteville, North Carolina
Robert M. Guthrie, MD
College of Medicine and Public Health
Ohio State University
Terrance Killilea, PharmD
Vice President of Pharmacy
Regence Blue Shield of Idaho
James M. McKenney, PharmD
Virginia Commonwealth University
President and Chief Executive Officer
National Clinical Research, Inc
It is the policy of The American Journal of Managed Care to have all faculty who participate in programs sponsored by pharmaceutical organizations disclose any real or apparent conflicts of interest.
These participants report relationships with the following pharmaceutical companies:
The following participants have declared no financial affiliations with corporate organizations:
We would like to thank Wayne Kuznar for editorial assistance in the development of two of these articles (as noted in footnotes).
Signed disclosures are on file at the office of The American Journal of Managed Care, Princeton, New Jersey.
This publication was made possible by a grant from AstraZeneca.
The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.